Skip to main content
main-content
Erschienen in: Diabetologia 2/2020

01.02.2020 | Consensus Report Update

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

verfasst von: John B. Buse, Deborah J. Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A. D’Alessio, Melanie J. Davies

Erschienen in: Diabetologia | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min−1 [1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.
Literatur
17.
Zurück zum Zitat Matthews DR, Paldánius PM, Proot P, Chiang YT, Stumvoll M, del Prato S (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394(10208):1519–1529. https://​doi.​org/​10.​1016/​S0140-6736(19)32131-2 CrossRefPubMed Matthews DR, Paldánius PM, Proot P, Chiang YT, Stumvoll M, del Prato S (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394(10208):1519–1529. https://​doi.​org/​10.​1016/​S0140-6736(19)32131-2 CrossRefPubMed
19.
20.
Zurück zum Zitat Frías JP, Guja C, Hardy E et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004–1016. https://​doi.​org/​10.​1016/​S2213-8587(16)30267-4 CrossRefPubMed Frías JP, Guja C, Hardy E et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004–1016. https://​doi.​org/​10.​1016/​S2213-8587(16)30267-4 CrossRefPubMed
Metadaten
Titel
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
verfasst von
John B. Buse
Deborah J. Wexler
Apostolos Tsapas
Peter Rossing
Geltrude Mingrone
Chantal Mathieu
David A. D’Alessio
Melanie J. Davies
Publikationsdatum
01.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 2/2020
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-05039-w

Weitere Artikel der Ausgabe 2/2020

Diabetologia 2/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.